Nob Hill Therapeutics, Inc. was formed to develop improved inhaled therapeutics targeting orphan drug indications and other lung diseases. We are leveraging a novel, first-in-class, dry powder nebulizer technology (DryNebTM). DryNeb minimizes drug formulation requirements and maximizes inhaled drug delivery to the lungs by using a mechanical respirable aerosol generation technology and a patient’s normal tidal breathing pattern.
The Problem: Traditional dry powder inhaler products (e.g., Advair Diskus, Tobi PodHalder, etc.) require patients to strongly inhale through the mouthpiece in order to deliver sufficient drug to the lungs. This process is inefficient as many patients with lung conditions have compromised pulmonary function and are not able to generate the force required to generate the powder aerosol and “breathe in” the drug.
The Solution: DryNeb overcomes these inefficiencies by utilizing only a patient’s normal breathing pattern combined with simple, battery-powered mechanical generation of highly respirable drug particles. The DryNeb patient-device interface operates much like normal breathing with a standard liquid nebulizer. However, the DryNeb requires no compressor, no liquid formulation, and has the capability to deliver the dose over a much shorter treatment time vs. a jet or vibrating mesh liquid nebulizer.
Market Opportunity: In 2019, the inhalation therapeutics and inhaler-device markets were approximately $25B and $10B each. Our lead product is an antifungal directed at treating the orphan indication Allergic Bronchopulmonary Aspergillosis (ABPA) in cystic fibrosis (CF) patients. NHT is also developing antibiotic treatments for CF-related nontuberculous mycobacterial (NTM) and exploring other orphan and serious lung indications, including deadly viral lung infections.
Investment information is restricted to VIN members. Become a member to view investment opportunities.